Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr;42(1):9-11.
doi: 10.5152/eajm.2010.03.

Distribution of HLA Tissue Groups in Patients with Gastric Cancer

Mehmet Bilici  1 , Nihat Okcu  1 , Kerim Cayır  1 , Ibrahim Pirim  2 , Salim B Tekin  1 , Cemal Gundogdu  3
Affiliations

Distribution of HLA Tissue Groups in Patients with Gastric Cancer

Mehmet Bilici et al. Eurasian J Med. 2010 Apr.

Abstract
in English, Turkish

Objective: Gastric cancer is an important disease that is seen all over the world and that threats public health. At the same time, gastric cancer is a heterogeneous disorder with multifactorial etiologies. Recent studies have shown a significant association between HLA antigens and gastric adenocarcinoma. The aim of the present study was to determine the distribution of HLA class I (HLA-A, B and C) and class II (HLA-DR, DQ and DP) antigens in Turkish patients with gastric adenocarcinoma.

Materials and methods: HLA alleles or HLA haplotypes associated with gastric cancer were established in the Turkish population using PSR-SSP analysis in 71 unrelated patients with gastric cancer and in 82 unrelated healthy controls. The statistical significance of differences in allele frequencies between patients and controls was measured by the Chi-square test with Yates's correction.

Results: The study revealed that the HLA-Cw5 antigen is more prevalent in patients with gastric cancer (p=0.042) and that the HLA-DRB1*15 antigen is more prevelent in the control group (p=0.021).

Conclusion: It is probable that HLA-Cw5 is a risk factor for gastric cancer whereas HLA-DRB1*15 plays a protective role for this disease. The results show that different loci on HLA may control resistance to or tendency for any disease in different societies; each society should determine its own tissue group.

Amaç: Mide kanseri tüm dünyada sık görülen ve toplum sağlığını tehdit eden önemli bir hastalıktır. Aynı zamanda mide kanseri multifaktöriyel etyolojiye sahip heterojen bir hastalıktır. Son zamanlarda yapılan çalışmalar HLA antijenleri ile mide adenokanserleri arasında önemli bir ilişki olduğunu gösterdi. Bu çalışmanın amacı, mide adenokanserli Türk hastalarda HLA sınıf I (HLA-A, B ve C) ve sınıf II (HLA-DR, DQ ve DP) antijenlerinlerinin dağılımını belirlemekti.

Gereç ve yöntem: 82 akraba olmayan sağlıklı kontrollerde ve 71 akraba olmayan mide kanserli hastalarda PSR-SSP analizi kullanılarak Türk populasyonunda HLA allelleri veya HLA haplotipleri ile mide kanseri arasındaki ilişki belirlendi. Hasta ve kontroller arasında alel sıklığındaki istatistiksel anlamlı farklılıklar Yates düzeltmeli ki-kare testi ile hesaplandı.

Bulgular: Çalışma, kontrol grubunda ise HLA-DRB1*15 antijeninin (p=0.021), mide kanserli hastalarda ise HLA-Cw5’in (p=0.042) istatistiksel olarak anlamlı olacağını ortaya çıkardı.

Sonuç: Muhtemel ki, HLA-Cw5 mide kanseri için mide kanseri için bir risk faktörü, HLA-DRB1*15 ise mide kanserine karşı koruyucu rol oynamaktadır. HLA üzerindeki farklı lokusların mide kanserine direnci veya yatkınlığı kontrol edebileceği kanısına varıldı. HLA antijenleri herhangi bir hastalıkta farklı toplumlarda farklı şekilde eksprese olacağından her toplum kendi doku grubunu belirlemelidir.

Keywords: Gastric cancer; HLA antigens; HLA-Cw5; HLA-DRB1*15.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Correa P, Haenszel W. Epidemiology of gastric cancer. In: Correa P, Haenszel W, editors. Epidemiology of Cancer of the Digestive Tract. The Hague: M Nijhoff; 1982. pp. 58–84.
    1. Correa P. The epidemiology of gastric cancer. World J Surg. 1991;15:228–34. - PubMed
    1. Kunisaki C, Shimada H, Yamaoka H, et al. Indications for paraaortic lymph node dissection in gastric cancer patients with paraaortic lymph node involvement. Hepatol Gastroenterol. 2000;47:586–9. - PubMed
    1. Abe R, Akiyoshi T, Baba T. Two-route chemotherapy using cisplatin and its neutralizing agent, sodium thiosulfate, for intraperitoneal cancer. Oncology. 1990;47:422–6. - PubMed
    1. Luk GD. Tumors of the Stomach. In: Feldman M, Sleisenger MH, Scharschmidt BF, editors. Gastrointestinal and Liver Disease. Philadelphia: W.B. Saunders Company; 1998. pp. 733–49.

LinkOut - more resources